1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Hypertension - Pipeline Review, H1 2020, provides an overview of the Hypertension (Cardiovascular) pipeline landscape.
Hypertension, also referred to as high blood pressure, is a condition in which the arteries have persistently elevated blood pressure. Many factors can affect blood pressure, including hormone levels, water and salt levels in body and condition of kidneys, nervous system, or blood vessels. Most people with high blood pressure have no signs or symptoms, even if blood pressure readings reach dangerously high levels. Although a few people with early-stage high blood pressure may have dull headaches, dizzy spells or a few more nosebleeds than normal, these signs and symptoms typically don't occur until high blood pressure has reached a severe.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Hypertension - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Hypertension (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hypertension (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 8, 1, 33, 37, 27, 3, 85, 29 and 10 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 21 and 8 molecules, respectively.
Hypertension (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hypertension (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Hypertension (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hypertension (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hypertension (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hypertension (Cardiovascular)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hypertension (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hypertension (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Hypertension - Overview
- Hypertension - Therapeutics Development
- Hypertension - Therapeutics Assessment
- Hypertension - Companies Involved in Therapeutics Development
- Hypertension - Drug Profiles
- Hypertension - Dormant Projects
- Hypertension - Discontinued Products
- Hypertension - Product Development Milestones
- Appendix
List of Tables
- Number of Products under Development for Hypertension, H1 2020
- Number of Products under Development by Companies, H1 2020
- Number of Products under Development by Universities/Institutes, H1 2020
- Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
- Products under Development by Companies, H1 2020
- Products under Development by Universities/Institutes, H1 2020
- Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
- Number of Products by Stage and Target, H1 2020
- Number of Products by Stage and Mechanism of Action, H1 2020
- Number of Products by Stage and Route of Administration, H1 2020
- Number of Products by Stage and Molecule Type, H1 2020
- Hypertension - Pipeline by Aadi Bioscience Inc, H1 2020
- Hypertension - Pipeline by Abivax SA, H1 2020
- Hypertension - Pipeline by Acceleron Pharma Inc, H1 2020
- Hypertension - Pipeline by Actelion Pharmaceuticals Ltd, H1 2020
- Hypertension - Pipeline by Addpharma Inc, H1 2020
- Hypertension - Pipeline by Adepthera LLC, H1 2020
- Hypertension - Pipeline by Adhera Therapeutics, H1 2020
- Hypertension - Pipeline by Aerami Therapeutics, H1 2020
- Hypertension - Pipeline by Aerogen Ltd, H1 2020
- Hypertension - Pipeline by Aggamin LLC, H1 2020
- Hypertension - Pipeline by AI Therapeutics, H1 2020
- Hypertension - Pipeline by Ajanta Pharma Ltd, H1 2020
- Hypertension - Dormant Projects, H1 2020
- Hypertension - Discontinued Products, H1 2020
List of Figures
- Number of Products under Development for Hypertension, H1 2020
- Number of Products under Development by Companies, H1 2020
- Number of Products under Development by Universities/Institutes, H1 2020
- Number of Products by Top 10 Targets, H1 2020
- Number of Products by Stage and Top 10 Targets, H1 2020
- Number of Products by Top 10 Mechanism of Actions, H1 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
- Number of Products by Top 10 Routes of Administration, H1 2020
- Number of Products by Stage and Top 10 Routes of Administration, H1 2020
- Number of Products by Top 10 Molecule Types, H1 2020
- Number of Products by Stage and Top 10 Molecule Types, H1 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Aadi Bioscience Inc
- Abivax SA
- Acceleron Pharma Inc
- Actelion Pharmaceuticals Ltd
- Addpharma Inc
- Adepthera LLC
- Adhera Therapeutics
- Aerami Therapeutics
- Aerogen Ltd
- Aggamin LLC
- AI Therapeutics
- Ajanta Pharma Ltd
- Alnylam Pharmaceuticals Inc
- Altavant Sciences Inc
- Alterras Therapeutics GmbH
- AMAG Pharmaceuticals Inc
- AnGes Inc
- AOBiome LLC
- Apaxen
- APEIRON Biologics AG
- Apollo Therapeutics LLC
- APT Therapeutics Inc
- Aqualung Therapeutics Corp
- Attgeno AB
- ATXA Therapeutics Ltd
- AVEO Oncology Inc
- Bayer AG
- Beijing Wehand-Bio Pharmaceutical Co Ltd
- Bial - Portela & Ca SA
- Biogen Inc
- BioRestorative Therapies Inc
- Boehringer Ingelheim International GmbH
- Boryung Pharmaceutical Co Ltd
- Bristol-Myers Squibb Co
- C4X Discovery Holdings Plc
- Camurus AB
- Capricor Therapeutics Inc
- CardioPharma Inc
- CellionBioMed Inc
- Cellmid Ltd
- Celsion Corp
- Celtaxsys Inc
- Cereno Scientific AB
- Chiesi Farmaceutici SpA
- Chong Kun Dang Pharmaceutical Corp
- Chugai Pharmaceutical Co Ltd
- CinCor Pharma Inc
- Close Loop Medicine Ltd
- Complexa Inc
- Cumberland Pharmaceuticals Inc
- D. Western Therapeutics Institute Inc
- Daewon Pharmaceutical Co Ltd
- Daewoong Co Ltd
- Daewoong Pharmaceutical Co Ltd
- Daiichi Sankyo Co Ltd
- Denovo Biopharma LLC
- Dongkook Pharmaceutical Co Ltd
- Eldrug SA
- Eli Lilly and Co
- Elyson Pharmaceutical Co Ltd
- Excubio Pharmaceuticals Inc
- Ferring Pharmaceuticals Inc
- FunPep Co Ltd
- Galectin Therapeutics Inc
- GenKyoTex SA
- GenThera Inc
- GEXVal Inc
- Gilead Sciences Inc
- Gmax Biopharm Ltd
- Gossamer Bio Inc
- Guangzhou Magpie Pharmaceutical Co Ltd
- H. Lundbeck AS
- Hanmi Pharmaceuticals Co Ltd
- Hetero Labs Ltd
- Himuka AM Pharma Corp
- HK inno.N Corp
- Idorsia Pharmaceutical Ltd
- Innolife Co Ltd
- Innopharmax Inc
- Insmed Inc
- Insys Therapeutics Inc
- Interprotein Corp
- Inven2 AS
- INVENT Pharmaceuticals Inc
- Ionis Pharmaceuticals Inc
- Jeil Pharmaceutical Co Ltd
- Jiangsu Hengrui Medicine Co Ltd
- KBP BioSciences Co Ltd
- Keros Therapeutics Inc
- Kyowa Kirin Co Ltd
- Kyung Dong Co Ltd
- Larix Bioscience LLC
- Lee's Pharmaceutical Holdings Ltd
- Les Laboratoires Servier SAS
- LG Chem Ltd
- Liaoning Haiwang Biotechnoloty Co Ltd
- LinXis BV
- Liquidia Technologies Inc
- LTT Bio-Pharma Co Ltd
- Martin Pharmaceuticals Inc
- Merck & Co Inc
- Mezzion Pharma Co Ltd
- Mifcare
- Morphogen-IX Ltd
- Nadian Bio Ltd
- NeuroBo Pharmaceuticals Inc
- Nippon Shinyaku Co Ltd
- Nissan Chemical Corp
- Noorik Biopharmaceuticals AG
- Northern Therapeutics Inc
- Novartis AG
- NuSirt Biopharma Inc
- Omeros Corp
- Orion Corp
- Overseas Pharmaceuticals Ltd
- Panorama Research Inc
- Park Active Molecules
- Pfizer Inc
- Pharming Group NV
- Pharmosa Biopharm Inc
- PhaseBio Pharmaceuticals Inc
- PHPrecisionMed LLC
- Proteo Inc
- Pulmokine Inc
- Q BioMed Inc
- QR Pharmaceuticals Ltd
- Quantum Genomics SA
- Radikal Therapeutics Inc
- Reata Pharmaceuticals Inc
- Recursion Pharmaceuticals Inc
- Relief Therapeutics Holding AG
- Relypsa Inc
- Renova Therapeutics Inc
- Respira Therapeutics Inc
- Resverlogix Corp
- Reviva Pharmaceuticals Inc
- Ridge Therapeutics LLC
- RMJ Holdings LLC
- Samik Pharmaceutical Co Ltd
- Sarfez Pharmaceuticals Inc
- Schrodinger LLC
- Scohia Pharma Inc
- Shanghai Pharmaceutical Group Co Ltd
- Shanghai Xinyi Pharmaceutical Co Ltd
- Shenzhen Salubris Pharmaceuticals Co Ltd
- SJT Molecular Research SL
- Sorrento Therapeutics Inc
- Sosei Heptares
- SteadyMed Therapeutics Inc
- Stocosil Inc
- Suda Pharmaceuticals Ltd
- Sulfateq BV
- Synokem Pharmaceuticals Ltd
- Takeda Pharmaceutical Co Ltd
- Target Medicals LLC
- Theracos Inc
- Theragene Pharmaceuticals Inc
- Theravance Biopharma Inc
- Topadur Pharma AG
- Translate Bio Inc
- Tritech Biopharmaceuticals Co Ltd
- United Therapeutics Corp
- Vascular BioSciences
- Vasculonics LLC
- VasThera Co Ltd
- Vectus Biosystems Ltd
- Velocity Pharmaceutical Development LLC
- VG Life Sciences Inc
- Vivus Inc
- Windtree Therapeutics Inc
- XuanZhu Pharma Co Ltd
- Yuhan Corp
- Zhejiang Conba Pharmaceutical Co Ltd
